[Early antiviral treatment response in HBeAg-positive chronic HBV infected-patients with high viral load and normal ALT].

ABSTRACT

The diagnosis and treatment rates of hepatitis B virus (HBV) infection in China in 2020 were 22.1% and 15.0%, respectively, according to the Polaris Observatory HBV Collaborators report. This is still far below the World Health Organization's 2030 hepatitis B elimination target (90% and 80%, respectively, for the diagnosis and treatment rates). Although China has promulgated and implemented a series of policies to eliminate the hepatitis B virus, there are still many HBV infected patients who need to be detected and treated. It has been contoversial whether HBeAg-positive chronic HBV infected-patients with high viral load and normal alanine aminotransferase (ALT), also known as the "immune-tolerant phase," should receive anti-HBV therapy. Hepatologists should pay attention to the patient population known as "immune tolerant," as well as the continuous accumulation of evidence-based medical evidence for early antiviral therapy response. The current focus is on discussing the pros and cons of receiving and recommending anti-HBV therapy at this time for the management of these patients.